V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330006889 | 330003655 | 1.8 | 24 | Curative (C) | 2015-11-16 | 2016-02-01 | Cisplatin 7 day | N | N | 330005649 | CISPLATIN |
| 330006890 | 330003656 | 0 | 104 | Neo-adjuvant (N) | 2017-12-30 | 2018-02-13 | METHOTREXATE | Y | Y | 330005651 | METHOTREXATE |
| 330006891 | 330003656 | 1.9 | 81 | null | 2013-08-19 | 2014-03-25 | Mifamurtide weeks 1-12 | N | N | 330005651 | MIFAMURTIDE |
| 330006893 | 330003658 | 1.88 | 81.1 | Adjuvant (A) | 2016-01-29 | 2016-11-28 | MIFAMURTIDE | N | null | 330005676 | MIFAMURTIDE |
| 330006894 | 330003660 | 1.85 | null | Curative (C) | 2017-01-12 | 2017-01-12 | EW EuroEwing 2012 Arm A VAI | N | N | 330005679 | TRIAL |
| 330006895 | 330003660 | null | null | Adjuvant (A) | 2017-08-18 | 2017-08-18 | Cisplatin | N | N | 330005679 | CISPLATIN |
| 330006896 | 330007976 | 1.02 | 77.6 | Neo-adjuvant (N) | 2018-08-04 | 2018-08-07 | LUX TRIAL | N | N | 330005686 | TRIAL |
| 330006897 | 330003669 | null | null | Neo-adjuvant (N) | null | 2016-05-04 | Cisplatin 7 day | null | null | 330005691 | CISPLATIN |
| 330006898 | 330007977 | null | 43.4 | Palliative (P) | null | 2016-03-27 | OST Euramos 1 Closed Trial - A | null | null | 330005694 | DOXORUBICIN |
| 330006899 | 330003672 | null | null | Adjuvant (A) | 2015-10-26 | 2015-12-11 | METHOTREXATE | N | N | 330005698 | METHOTREXATE |
| 330006900 | 330003673 | 0 | 74.7 | Palliative (P) | 2012-11-08 | 2013-05-08 | Trial Unspecified | null | null | 330005699 | TRIAL |
| 330006901 | 330003674 | 1.66 | null | Palliative (P) | 2012-12-09 | 2013-05-30 | R2W trial | N | N | 330005701 | TRIAL |
| 330006902 | 330003675 | 1.7 | 71 | Palliative (P) | 2016-01-15 | 2016-12-23 | DOXORUBICIN | N | N | 330005701 | DOXORUBICIN |
| 330006903 | 330003679 | 0 | 85 | Palliative (P) | null | 2017-05-17 | DOXORUBICIN | 02 | Y | 330005706 | DOXORUBICIN |
| 330006904 | 330003679 | 1.85 | 12 | Curative (C) | 2015-09-04 | 2015-10-03 | Cisplatin | null | null | 330005706 | CISPLATIN |
| 330006905 | 330003679 | 1.7 | 15.9 | Neo-adjuvant (N) | 2017-01-09 | 2017-03-29 | Cisplatin 7 day | N | N | 330005706 | CISPLATIN |
| 330006906 | 330003680 | 1.74 | null | null | 2016-05-29 | 2016-06-06 | Mifamurtide weeks 13-36 | N | Y | 330005719 | MIFAMURTIDE |
| 330006907 | 330003681 | 1.71 | 104.6 | Palliative (P) | 2014-07-10 | 2014-07-18 | MIFAMURTIDE | Y | Y | 330005721 | MIFAMURTIDE |
| 330006908 | 330003682 | 1.73 | 49.6 | Neo-adjuvant (N) | 2017-02-12 | 2017-06-06 | METHOTREXATE | 02 | N | 330005721 | METHOTREXATE |
| 330006909 | 330003686 | 1.8 | 100 | Adjuvant (A) | 2017-01-12 | 2017-01-24 | DOXORUBICIN | null | N | 330005735 | DOXORUBICIN |
| 330006910 | 330003688 | 1.71 | 86.2 | Curative (C) | 2015-12-11 | 2016-05-17 | EW EuroEwing 2012 Arm B IE | 02 | N | 330005735 | TRIAL |
| 330006911 | 330010332 | null | 46.2 | Neo-adjuvant (N) | 2014-08-04 | 2014-08-06 | DOXORUBICIN | 2 | N | 330005748 | DOXORUBICIN |
| 330006912 | 330003690 | 1.82 | null | Neo-adjuvant (N) | 2015-03-21 | 2015-03-21 | EW EuroEwing 2012 Arm B IE | N | N | 330005768 | TRIAL |
| 330006913 | 330003690 | 1.7 | 25.4 | Adjuvant (A) | 2016-08-23 | 2016-09-05 | MIFAMURTIDE | 02 | N | 330005768 | MIFAMURTIDE |
| 330006914 | 330003691 | 1.82 | 92.5 | Neo-adjuvant (N) | 2015-10-03 | 2016-04-11 | MIFAMURTIDE | N | N | 330005788 | MIFAMURTIDE |
| 330006915 | 330003691 | 1.54 | 77.4 | Neo-adjuvant (N) | 2018-05-17 | 2018-07-04 | METHOTREXATE | N | N | 330005788 | METHOTREXATE |
| 330006916 | 330003691 | 1.83 | 62.4 | Neo-adjuvant (N) | 2013-05-12 | 2013-11-06 | Doxorubicin 75mg/m2 | N | N | 330005788 | DOXORUBICIN |
| 330006917 | 330003693 | 1.77 | 108.2 | Curative (C) | 2017-07-23 | 2017-08-02 | METHOTREXATE | Y | N | 330005832 | METHOTREXATE |
| 330006918 | 330007989 | 1.69 | 63 | Curative (C) | null | 2017-11-24 | OST Mifamurtide | N | N | 330005833 | MIFAMURTIDE |
| 330006919 | 330010335 | 1.63 | 51.2 | null | null | 2017-04-08 | DOXORUBICIN | N | null | 330005834 | DOXORUBICIN |
| 330006920 | 330010335 | 1.77 | 86 | Adjuvant (A) | 2017-07-09 | 2017-07-21 | Mifamurtide weeks 1-12 | 02 | Y | 330005834 | MIFAMURTIDE |
| 330006921 | 330010335 | 1.63 | 31 | Curative (C) | 2017-03-25 | 2017-06-04 | Cisplatin | 2 | N | 330005834 | CISPLATIN |
| 330006922 | 330012760 | 1.65 | 31 | Neo-adjuvant (N) | 2014-11-29 | 2015-04-17 | MIFAMURTIDE | 02 | N | 330005860 | MIFAMURTIDE |
| 330006923 | 330013011 | 1.75 | 72.4 | Palliative (P) | 2015-09-30 | 2015-10-03 | EW EuroEwing 2012 Arm A VAI | 02 | N | 330005860 | TRIAL |
| 330006924 | 330003696 | 1.72 | 89.4 | Adjuvant (A) | 2013-06-30 | 2014-02-28 | OST Euramos 1 Closed Trial - A | N | N | 330005861 | DOXORUBICIN |
| 330006925 | 330003697 | null | null | Adjuvant (A) | 2015-09-10 | 2015-09-11 | OST Mifamurtide | N | N | 330005868 | MIFAMURTIDE |
| 330006926 | 330003700 | 1.47 | 112 | Neo-adjuvant (N) | 2013-08-08 | 2013-08-21 | Trial Unspecified | N | N | 330005882 | TRIAL |
| 330006927 | 330003702 | 0 | 162.9 | Curative (C) | 2016-12-10 | 2016-12-10 | EW EuroEwing 2012 Arm A VAI | 01 | N | 330005885 | TRIAL |
| 330006928 | 330003704 | 1.6 | 65.2 | Curative (C) | 2017-09-06 | 2017-12-19 | MIFAMURTIDE | 02 | N | 330005891 | MIFAMURTIDE |
| 330006929 | 330003704 | 1.79 | 80.9 | Curative (C) | null | 2016-07-20 | Mifamurtide weeks 1-12 | null | null | 330005891 | MIFAMURTIDE |
| 330006930 | 330003706 | 1.83 | 88 | Palliative (P) | 2015-02-06 | 2015-02-27 | Trial Unspecified | N | N | 330005903 | TRIAL |
| 330006931 | 330003706 | 1.68 | 81 | Adjuvant (A) | 2015-03-03 | 2015-10-17 | OST Mifamurtide | 1 | null | 330005903 | MIFAMURTIDE |
| 330006932 | 330003706 | 1.6 | 160 | Disease modification (D) | 2017-10-20 | 2017-10-23 | METHOTREXATE | N | N | 330005903 | METHOTREXATE |
| 330006933 | 330003709 | 1.7 | 54.8 | Palliative (P) | 2016-09-07 | 2016-09-09 | METHOTREXATE | 02 | Y | 330005922 | METHOTREXATE |
| 330006934 | 330003710 | 1.64 | 43.5 | Palliative (P) | 2015-04-18 | 2016-01-09 | DOXORUBICIN | N | N | 330005927 | DOXORUBICIN |
| 330006935 | 330003710 | 1.78 | 83 | null | 2012-05-10 | 2013-10-31 | MIFAMURTIDE | N | N | 330005927 | MIFAMURTIDE |
| 330006938 | 330003716 | 1.73 | 102.9 | Adjuvant (A) | 2014-12-02 | 2015-04-22 | MIFAMURTIDE | N | N | 330005948 | MIFAMURTIDE |
| 330006939 | 330003719 | 1.83 | 73.8 | Palliative (P) | null | 2016-06-09 | MIFAMURTIDE | null | null | 330005950 | MIFAMURTIDE |
| 330006940 | 330003720 | 1.7 | 61.2 | Disease modification (D) | 2014-08-23 | 2014-09-23 | Trial Unspecified | Y | Y | 330005950 | TRIAL |
| 330006941 | 330003720 | 0 | 80.9 | Adjuvant (A) | 2016-11-16 | 2016-11-16 | MIFAMURTIDE | N | N | 330005950 | MIFAMURTIDE |